Home Science & Medicine Targeted Therapy

Targeted Therapy

Feature articles about advances and current developments in targeted therapy that have significant impact or impact potential on thoracic oncology.

ALK Testing in Europe

By Enriqueta Felip, MD, PhD Posted: February 2018 ALK-directed TKIs are effective first- and second-line therapies in patients with ALK rearrangements. Testing of all patients with...

Q & A with Yi-Long Wu, MD

What is the current standard of care in the adjuvant setting post-resection of high-risk NSCLC in your practice or nationally? Posted: October 2017 Current Chinese Lung...

Clinical Labeling in Medicinal Products: An Interview With Dr. David Planchard About the Effects...

By David Planchard, MD, PhD What was the rationale for conducting clinical research in BRAF mutationpositive NSCLC? Recently, progress has been made in characterization of the...

Afatinib Outperforms Gefitinib in Advanced Non-Small Cell Lung Cancer

By Erik J. MacLaren, PhD The pan-ErbB inhibitor afatinib (Gilotrif) improves progression-free survival (PFS), time-to-treatment-failure (TTF) rate, and objective response rate (ORR) compared to the...

ADJUVANT Trial of Gefitinib Versus Chemotherapy in Resected EGFR-Mutations Non-Small Cell Lung Cancer

By Heather Wakelee, MD Posted: October 2017 For most of the world, four cycles of cisplatin-based adjuvant chemotherapy is the standard of care for patients with...

The Lung Master Protocol (Lung-MAP)

By Vassiliki A. Papadimitrakopoulou, MD Lung-MAP (S1400), is a unique master multi-study protocol that incorporates genomic testing of tumors through a next-generation sequencing (NGS) platform...

Updated Results from the Phase III ALEX Trial: Embracing Hazard Ratios

By D. Ross Camidge, MD, and Mary W. Redman, PhD Posted: August 2018 Updates of the primary analysis of the phase III ALEX trial were presented...

Uncommon Oncogenic Drivers in NSCLC

By Karen L. Reckamp, MD, MS Posted: March 1, 2019  Identification of genetic alterations in NSCLC has transformed diagnosis and treatment for patients with advanced disease....

Meeting News